PA
United Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tyvaso DPI | Pulmonary Arterial Hypertension (PAH) & PH-ILD | Approved |
| Ralinepag | Pulmonary Arterial Hypertension (PAH) | Phase 3 |
| Beraprost MR | Pulmonary Arterial Hypertension (PAH) | Phase 3 |
| Gene Therapy for ADA-SCID | Adenosine Deaminase Deficient SCID | Preclinical |
| UThymoKidney (Xenokidney) | End-Stage Renal Disease | Clinical (Expanded Access) |
| Xenolung | End-Stage Lung Disease | Preclinical |
| XRapid EVLP | Donor Lung Rehabilitation | Commercial |
Leadership Team at United Therapeutics
MR
Martine Rothblatt
Founder, Chairperson & Chief Executive Officer
MB
Michael Benkowitz
President & Chief Operating Officer
JE
James Edgemond
Chief Financial Officer & Treasurer
DZ
David Zaccardelli
President, Pharmaceutical Development & Manufacturing
JF
John Ferrari
Chief Strategy Officer